Skip to main content
Premium Trial:

Request an Annual Quote

Aushon Enters Predictive Dx Deal with Peking University

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aushon BioSystems today said that it has signed a letter of intend to collaborate with Peking University Cancer Hospital on the development of predictive diagnostic markers for liver metastases of colorectal cancer.

The collaboration will use Aushon's protein biomarker detection technologies and stratification biomarkers for radio-chemotherapy patients. The partners expect to negotiate an agreement to provide Aushon with exclusive rights in North America and Europe to certain intellectual property generated from the collaboration for diagnostic applications.

Jin Gu, a professor and clinician at PUCH, will lead the research.

"We believe Aushon's technology and expertise are ideally suited for this diagnostic development program and expect that this will be the first of several such technical collaborations with Peking University Cancer Hospital and other leading research institutions in Asia," Joe Blanchard, COO of Billerica, Mass.-based Aushon, said in a statement.

A few months ago, Aushon signed a deal with LightArray Biotech to provide the firm's multiplex biomarker products and services in China.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.